Onconova Therapeutics, Inc. — Q1 2016 Form 10-Q
Entity note: The supplied filing is for Onconova Therapeutics, Inc., not Traws Pharma, Inc. It covers the unaudited quarter ended March 31, 2016; comparisons are with Q1 2015 unless otherwise noted.
Business context
Onconova is a clinical-stage oncology biopharmaceutical company, with most development effort focused on rigosertib. Its Phase 3 INSPIRE trial is testing intravenous rigosertib in higher-risk MDS patients after HMA failure. The company also reports other clinical and preclinical programs.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Revenue | $1.474 million | $0.114 million |
| Operating expenses | $8.994 million | $12.463 million |
| Operating loss | $7.520 million | $12.349 million |
| Net loss | $7.240 million | $12.367 million |
| Net loss per share | $0.27 | $0.57 |
| Cash used in operations | $4.579 million | $9.854 million |
- Revenue was primarily collaboration revenue: $1.221 million from Baxalta for INSPIRE cost sharing and $0.253 million from SymBio. It was not reported as product sales.
- Research and development expense fell 39% to $5.822 million, mainly reflecting lower spending on other studies and programs, partly offset by INSPIRE costs. General and administrative expense rose 7% to $3.172 million.
- Cash and cash equivalents were $16.835 million at quarter-end, down from $19.799 million at December 31, 2015. Working capital was $11.8 million; accumulated deficit was $325.797 million.
- Total liabilities were $12.823 million, including a $0.295 million warrant liability and deferred revenue. The balance sheet reports no borrowings; debt is not otherwise discussed as a material funding source.
- There is no meaningful positive operating margin: the company remained loss-making. Cash flow from investing activities was zero; financing provided $1.609 million net from a January stock-and-warrant issuance.
Material changes and unusual items
- Baxalta notified Onconova on March 3, 2016 that it would terminate the European rigosertib development and license agreement effective August 30, 2016. The European rights are then to revert to Onconova at no cost, but related future funding, milestones, and royalties from Baxalta will end. The company said it would seek to maximize Baxalta’s contractual contribution to INSPIRE; the amount to be received is uncertain.
- In February, the company reduced its workforce by a net six employees, about 17% of staff. It recorded a one-time $2.8 million severance-related charge, including $1.6 million of noncash accelerated stock compensation.
- January financing issued 1,936,842 shares and warrants for 968,421 shares, generating about $1.609 million net. The warrants are liability-classified and measured at fair value.
- Q1 net loss improved versus 2015, alongside lower operating expenses and higher collaboration revenue. The filing attributes expense reductions to cost controls and reduced activity in non-core, legacy, and other studies.
Outlook, risks, and contingencies
- Management estimated that cash, together with anticipated Baxalta INSPIRE cost-sharing payments, would fund ongoing trials and operations into Q1 2017. It also stated that substantial doubt exists about the company’s ability to continue as a going concern and that additional financing is required.
- Management expected cash expenditures in 2016 to decline from 2015 due to lower administrative and non-core trial costs, partly offset by rising INSPIRE spending as sites open and enrollment increases. If financing is unavailable, trials and other activities may be delayed, scaled back, or eliminated.
- INSPIRE began enrolling in December 2015, targets approximately 225 patients at more than 100 sites, and has overall survival as its primary endpoint. Topline data were anticipated in 2018. On April 25, 2016, 44 sites were reported open.
- The prior ONTIME Phase 3 study did not meet its primary endpoint. The company’s clinical, regulatory, financing, collaboration, and commercialization plans remain subject to significant uncertainty.
- Other program risks include a full clinical hold on briciclib following a drug-product lot testing failure; GBO’s two preclinical programs had not advanced to clinical stage, and discussions with GVK regarding GBO’s future were ongoing.
- The company reported no pending material legal proceedings and no material changes to risk factors from its 2015 Form 10-K. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Confirm the issuer identity: this filing names Onconova Therapeutics, Inc., despite the request metadata naming Traws Pharma, Inc.
- Track actual cash burn, financing proceeds, and whether the stated runway into Q1 2017 was achieved.
- Verify Baxalta cost-sharing receipts and the consequences of its August 2016 termination for INSPIRE funding and European rights.
- Monitor INSPIRE site activation, enrollment, trial costs, and the timing and outcome of interim and topline analyses.
- Assess potential dilution from the January warrants and any additional equity financing, and monitor progress or status changes for other clinical programs.